Publications by authors named "Elena Michaels"
Article Synopsis
- The CREATE-X trial showed that adjuvant capecitabine can improve survival for high-risk triple-negative breast cancer patients, but the standard dose is often hard to tolerate for many in the US.
- A retrospective study at the University of Chicago Medicine evaluated the safety and tolerability of capecitabine in 67 TNBC patients, looking specifically at their relative dose intensity (RDI) and side effects over eight treatment cycles.
- Results indicated that the average RDI was significantly lower than in the CREATE-X trial, with hand-foot syndrome, diarrhea, and fatigue being the most common side effects; the study found no major differences in tolerability based on age, race, BMI, or initial dosage.
Article Synopsis
- Triple-negative breast cancer (TNBC) is a serious and aggressive type of breast cancer with a high chance of returning and a generally poor outlook for patients.
- Recent advancements in understanding TNBC's variability have shown that some cases may respond well to immunotherapy, prompting research into this treatment approach for both early and advanced stages of the disease.
- The review highlights the biological reasons for using immunotherapy in TNBC, summarizes key trial findings that support its approval, and discusses the need for identifying biomarkers and developing new treatment combinations to enhance patient outcomes.
This review provides an outline of a risk-based approach to breast cancer screening and prevention. All women should be assessed for breast cancer risk starting at age 18 with identification of modifiable and non-modifiable risk factors. Patients can then be stratified into average, moderate, and high-risk groups with personalized screening and prevention plans.
View Article and Find Full Text PDFThe evolving therapeutic landscape of antibody-drug conjugates in breast cancer.
Expert Rev Anticancer Ther
December 2022
Introduction: Antibody-drug conjugates (ADCs) are a relatively new class of anti-cancer therapies approved for a number of malignancies, including breast cancer. Their unique structure, consisting of a monoclonal antibody connected via a linker to a toxic payload, combines characteristics of both targeted therapy and chemotherapy.
Areas Covered: In this review, we discuss the unique molecular structure and pharmacologic principles of ADCs and present the clinical efficacy and relevant toxicities of ADCs both approved and in development.
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). MET exon 14 skipping mutations occur in 3-4% of patients with NSCLC, while MET amplifications are found in 1-6% of patients.
View Article and Find Full Text PDFPurpose: Stroke survivors develop late complications after stroke (LCAS) that impair return to pre-stroke responsibilities. Optimal strategies for detection have not been developed. We assessed differences in LCAS symptom detection among young stroke survivors undergoing active surveillance versus usual care.
View Article and Find Full Text PDF